Analyst Ratings For Aileron Therapeutics Inc (NASDAQ:ALRN)
Today, HC Wainwright initiated coverage on Aileron Therapeutics Inc (NASDAQ:ALRN) with a Buy.
There are 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Aileron Therapeutics Inc (NASDAQ:ALRN) is Buy with a consensus target price of N/A per share, a potential N/A.
Some recent analyst ratings include
- 3/11/2019-Aileron Therapeutics Inc (NASDAQ:ALRN) has coverage initiated with a Buy rating
- 8/11/2017-Aileron Therapeutics Inc (NASDAQ:ALRN) had its Buy rating reiterated by Canaccord Genuity with a $19.00 price target
- 7/24/2017-Aileron Therapeutics Inc (NASDAQ:ALRN) has coverage initiated with a Outperform ➝ Outperform rating
- 7/24/2017-Aileron Therapeutics Inc (NASDAQ:ALRN) has coverage initiated with a Buy ➝ Buy rating and $19.00 price target
- 7/24/2017-Aileron Therapeutics Inc (NASDAQ:ALRN) has coverage initiated with a Buy ➝ Buy rating and $20.00 price target
- On 8/20/2018 Bioventures Ltd Novartis, Major Shareholder, sold 20,388 with an average share price of $2.30 per share and the total transaction amounting to $46,892.40.
- On 8/17/2018 Bioventures Ltd Novartis, Major Shareholder, sold 17,508 with an average share price of $2.10 per share and the total transaction amounting to $36,766.80.
- On 8/15/2018 Bioventures Ltd Novartis, Major Shareholder, sold 5,935 with an average share price of $2.21 per share and the total transaction amounting to $13,116.35.
- On 8/13/2018 Bioventures Ltd Novartis, Major Shareholder, sold 7,215 with an average share price of $2.42 per share and the total transaction amounting to $17,460.30.
- On 8/10/2018 John P Phd Longenecker, Insider, bought 10,000 with an average share price of $2.45 per share and the total transaction amounting to $24,500.00.
- On 8/9/2018 Bioventures Ltd Novartis, Major Shareholder, sold 1,235 with an average share price of $2.72 per share and the total transaction amounting to $3,359.20.
- On 8/7/2018 Bioventures Ltd Novartis, Major Shareholder, sold 4,681 with an average share price of $3.00 per share and the total transaction amounting to $14,043.00.
About Aileron Therapeutics Inc (NASDAQ:ALRN)
Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. It also develops next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Watertown, Massachusetts.
Recent Trading Activity for Aileron Therapeutics Inc (NASDAQ:ALRN)
Shares of Aileron Therapeutics Inc closed the previous trading session at 1,45 −0,040 2,68 % with 33500 shares trading hands.
